399 related articles for article (PubMed ID: 12610179)
1. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
3. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
8. Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.
Noda E; Maeda K; Inoue T; Nishihara T; Nishiguchi Y; Ohira M; Hirakawa K
Anticancer Res; 2006; 26(6C):4653-8. PubMed ID: 17214322
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Aschele C; Debernardis D; Casazza S; Antonelli G; Tunesi G; Baldo C; Lionetto R; Maley F; Sobrero A
J Clin Oncol; 1999 Jun; 17(6):1760-70. PubMed ID: 10561213
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Yamada H; Ichikawa W; Uetake H; Shirota Y; Nihei Z; Sugihara K; Hirayama R
Clin Colorectal Cancer; 2001 Nov; 1(3):169-73; discussion 174. PubMed ID: 12450430
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Johnston PG; Mick R; Recant W; Behan KA; Dolan ME; Ratain MJ; Beckmann E; Weichselbaum RR; Allegra CJ; Vokes EE
J Natl Cancer Inst; 1997 Feb; 89(4):308-13. PubMed ID: 9048835
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Cascinu S; Aschele C; Barni S; Debernardis D; Baldo C; Tunesi G; Catalano V; Staccioli MP; Brenna A; Muretto P; Catalano G
Clin Cancer Res; 1999 Aug; 5(8):1996-9. PubMed ID: 10473077
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
Findlay MP; Cunningham D; Morgan G; Clinton S; Hardcastle A; Aherne GW
Br J Cancer; 1997; 75(6):903-9. PubMed ID: 9062414
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Kamoshida S; Matsuoka H; Shiogama K; Matsuyama A; Shimomura R; Inada K; Maruta M; Tsutsumi Y
Pathol Int; 2004 Aug; 54(8):564-75. PubMed ID: 15260847
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
Berglund A; Edler D; Molin D; Nordlinder H; Graf W; Glimelius B
Anticancer Res; 2002; 22(6B):3653-9. PubMed ID: 12552972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
